These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 21803750)

  • 1. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
    Higgs BW; Liu Z; White B; Zhu W; White WI; Morehouse C; Brohawn P; Kiener PA; Richman L; Fiorentino D; Greenberg SA; Jallal B; Yao Y
    Ann Rheum Dis; 2011 Nov; 70(11):2029-36. PubMed ID: 21803750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
    Higgs BW; Zhu W; Richman L; Fiorentino DF; Greenberg SA; Jallal B; Yao Y
    Int J Rheum Dis; 2012 Feb; 15(1):25-35. PubMed ID: 22324944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased CD161+CD8+ T cells in the peripheral blood of patients suffering from rheumatic diseases.
    Mitsuo A; Morimoto S; Nakiri Y; Suzuki J; Kaneko H; Tokano Y; Tsuda H; Takasaki Y; Hashimoto H
    Rheumatology (Oxford); 2006 Dec; 45(12):1477-84. PubMed ID: 16638798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.
    Bilgic H; Ytterberg SR; Amin S; McNallan KT; Wilson JC; Koeuth T; Ellingson S; Newman B; Bauer JW; Peterson EJ; Baechler EC; Reed AM
    Arthritis Rheum; 2009 Nov; 60(11):3436-46. PubMed ID: 19877033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
    Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
    J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus.
    Biesen R; Demir C; Barkhudarova F; Grün JR; Steinbrich-Zöllner M; Backhaus M; Häupl T; Rudwaleit M; Riemekasten G; Radbruch A; Hiepe F; Burmester GR; Grützkau A
    Arthritis Rheum; 2008 Apr; 58(4):1136-45. PubMed ID: 18383365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large macrophage colony-forming cells identical to high proliferative potential colony-forming cells in peripheral blood of patients with collagen vascular diseases: high occurrence among patients with systemic sclerosis and dermatomyositis.
    Horie S; Minota S; Kano S
    J Rheumatol; 2000 Oct; 27(10):2378-81. PubMed ID: 11036833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Voskuyl AE; Rustenburg F; Baggen JM; Ibrahim SM; Fero M; Dijkmans BA; Tak PP; Verweij CL
    Ann Rheum Dis; 2007 Aug; 66(8):1008-14. PubMed ID: 17223656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
    Russo K; Hoch S; Dima C; Varga J; Teodorescu M
    J Rheumatol; 2000 Jan; 27(1):142-8. PubMed ID: 10648030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis.
    Hepburn AL; Mason JC; Davies KA
    Rheumatology (Oxford); 2004 May; 43(5):547-54. PubMed ID: 14747618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of large macrophage colony forming cells in the peripheral blood of patients with rheumatoid arthritis.
    Horie S; Nakada K; Masuyama J; Yoshio T; Minota S; Wakabayashi Y; Hirose S; Kano S
    J Rheumatol; 1997 Aug; 24(8):1517-21. PubMed ID: 9263144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.
    York MR; Nagai T; Mangini AJ; Lemaire R; van Seventer JM; Lafyatis R
    Arthritis Rheum; 2007 Mar; 56(3):1010-20. PubMed ID: 17328080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus.
    Nikpour M; Dempsey AA; Urowitz MB; Gladman DD; Barnes DA
    Ann Rheum Dis; 2008 Aug; 67(8):1069-75. PubMed ID: 18063674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
    Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis.
    Aguila LA; Lopes MR; Pretti FZ; Sampaio-Barros PD; Carlos de Souza FH; Borba EF; Shinjo SK
    Clin Rheumatol; 2014 Aug; 33(8):1093-8. PubMed ID: 24989017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rare case of systemic autoimmune disease with intricate features of systemic sclerosis, lupus, polymyositis and rheumatoid arthritis. Overlap syndrome or mixed connective tissue disease?
    Radulescu D; Pripon S; Ciovicescu F; Constantea NA
    Acta Reumatol Port; 2007; 32(3):292-7. PubMed ID: 17932479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.